Loading...
•
Mar 31, 2022
Personalis Q1 2022 Earnings Report
Personalis reported a decline in revenue due to lower VA MVP revenue, while biopharma revenue increased. The company is focused on expanding its clinical diagnostic team and collaborations.
Key Takeaways
Personalis reported a revenue of $15.2 million for Q1 2022, a decrease compared to $20.9 million in Q1 2021. The decrease was primarily due to a decline in revenue from the VA MVP program, offset by an increase in revenue from biopharma and other customers. Net loss for the quarter was $28.2 million, or $0.63 per share.
Total revenue was $15.2 million, down from $20.9 million year-over-year.
Biopharma and other customer revenue increased by 53% to $11.7 million, including $4.1 million from Natera.
VA MVP revenue decreased to $3.5 million from $13.2 million year-over-year.
Net loss was $28.2 million, or $0.63 per share.
Forward Guidance
Personalis expects total company revenue to be in the range of $62.0 million to $67.0 million for the full year 2022. Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.0 million to $60.0 million. Net loss is expected to be in the range of $110.0 million to $115.0 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...